Fierce Pharma

SEPTEMBER 22, 2023

Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break. Merck and Eisai’s Keytruda-Lenvima tag team can’t seem to catch a break.

Clinical Trials 118

Clinical Trials Clinical Trials Trials 118

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab), based on the high volume of RSAs arranged for these drugs. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

pharmaphorum

OCTOBER 29, 2021

Gilead’s Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan) will be paired with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in a new phase 3 trial in previously-untreated subjects with locally advanced or metastatic TNBC. While its headline revenue of $7.4

Trials 52

Trials Sales FDA Approval Production 52

XTalks

JANUARY 28, 2022

Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. The study evaluated the effectiveness of Kimmtrak against two immune checkpoint inhibitors (Merck’s Keytruda and Bristol Myers Squibb’s Yerboy) and the chemotherapy dacarbazine (as per clinician choice) used as conventional treatments for the disease.

FDA Approval 98

FDA Approval Development Licensing Licensing 98

pharmaphorum

JANUARY 5, 2021

First-line immunotherapy for NSCLC is dominated by Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab), transforming the prospects of some patients and propelling the drug to multibillion-dollar sales. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

pharmaphorum

APRIL 5, 2022

The one-year survival rate with the drug was 73%, compared to 58% in a group receiving standard-of-care – off-label immune checkpoint inhibitors used for other forms of melanoma like Merck & Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Yervoy (ipilimumab) or chemotherapy with dacarbazine.

Sales 52

Sales Protein Drugs Trials 52

XTalks

FEBRUARY 27, 2024

Addressing the high price tag, Iovance’s commercial chief Jim Ziegler said, “Payers have expressed their appreciation for the value proposition for Amtagvi.” The study is looking at Amtagvi in combination with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) versus Keytruda alone in patients with untreated melanoma.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52